NASDAQ:APVO Aptevo Therapeutics - APVO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.04 +0.02 (+0.99%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.95▼$2.1050-Day Range$1.74▼$2.4452-Week Range$1.65▼$7.20Volume175,208 shsAverage Volume76,718 shsMarket Capitalization$10.38 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aptevo Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside537.3% Upside$13.00 Price TargetShort InterestHealthy2.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.34Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($6.58) to ($6.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.55 out of 5 starsMedical Sector921st out of 1,009 stocksPharmaceutical Preparations Industry450th out of 494 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Aptevo Therapeutics has a forecasted upside of 537.3% from its current price of $2.04.Amount of Analyst CoverageAptevo Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.07% of the outstanding shares of Aptevo Therapeutics have been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently decreased by 30.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APVO. Previous Next 3.0 News and Social Media Coverage News SentimentAptevo Therapeutics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aptevo Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 17 people have searched for APVO on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.04% of the stock of Aptevo Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aptevo Therapeutics are expected to decrease in the coming year, from ($6.58) to ($6.87) per share.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 8.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aptevo Therapeutics (NASDAQ:APVO) StockAptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.Read More Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APVO Stock News HeadlinesMarch 30, 2023 | finance.yahoo.comAptevo Therapeutics Raises $9.6 Million in Non-Dilutive FundingMarch 30, 2023 | finance.yahoo.comAptevo Therapeutics Reports 2022 Financial Results and Provides Business UpdateMarch 31, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.January 9, 2023 | finance.yahoo.comAptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid TumorsDecember 20, 2022 | finance.yahoo.comAptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit RateDecember 14, 2022 | benzinga.comShort Volatility Alert: Aptevo TherapeuticDecember 12, 2022 | finance.yahoo.com100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)November 10, 2022 | finance.yahoo.comAptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsMarch 31, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.November 9, 2022 | finance.yahoo.comAlligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer TherapeuticsNovember 3, 2022 | finance.yahoo.comAptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and ExpositionOctober 1, 2022 | seekingalpha.comAPVO Aptevo Therapeutics Inc.September 19, 2022 | finance.yahoo.comAlligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 INDAugust 11, 2022 | finance.yahoo.comAptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsAugust 4, 2022 | nasdaq.comZymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue EstimatesJune 17, 2022 | msn.comAptevo Therapeutics's Return On Capital Employed OverviewJune 11, 2022 | seekingalpha.comAptevo gains after disclosing additional remission data in leukemia trialJune 9, 2022 | finance.yahoo.comAptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid LeukemiaMay 12, 2022 | finance.yahoo.comAptevo Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsApril 12, 2022 | finanznachrichten.deAptevo Therapeutics: APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual MeetingApril 12, 2022 | finance.yahoo.comAPVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual MeetingMarch 30, 2022 | morningstar.comAptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia | MorningstarMarch 29, 2022 | finance.yahoo.comAptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid LeukemiaMarch 24, 2022 | benzinga.comAptevo Therapeutics: Q4 Earnings InsightsMarch 24, 2022 | seekingalpha.comAptevo climbs as 2021 revenue more than doublesMarch 24, 2022 | msn.comWhy Did Aptevo Therapeutics Stock Jump 25% Today?March 24, 2022 | finance.yahoo.comAptevo Therapeutics Reports 2021 Financial Results and Provides Business UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APVO Company Calendar Last Earnings3/24/2022Today3/30/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APVO CUSIPN/A CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees54Year Founded2016Price Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+537.3%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,460,000.00 Net MarginsN/A Pretax Margin82.31% Return on Equity-370.26% Return on Assets-73.38% Debt Debt-to-Equity Ratio0.12 Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual Sales$12.29 million Price / Sales0.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book8.16Miscellaneous Outstanding Shares5,090,000Free Float4,883,000Market Cap$10.38 million OptionableOptionable Beta5.31 Social Links Key ExecutivesMarvin L. WhitePresident, Chief Executive Officer & DirectorJeffrey G. LamotheChief Operating Officer & Executive Vice PresidentDaphne L. TaylorChief Financial Officer & Senior Vice PresidentScott C. StromattChief Medical Officer & SVP-Clinical DevelopmentSoYoung KwonSenior VP-Human Resources & Corporate AffairsKey CompetitorsContext TherapeuticsNASDAQ:CNTXImunonNASDAQ:IMNNAptinyxNASDAQ:APTXDiffusion PharmaceuticalsNASDAQ:DFFNMinerva NeurosciencesNASDAQ:NERVView All CompetitorsInstitutional OwnershipMorgan StanleySold 7,501 shares on 2/15/2023Ownership: 0.222%Dimensional Fund Advisors LPBought 12,705 shares on 2/9/2023Ownership: 0.250%Bank of Montreal CanBought 10,000 shares on 2/1/2023Ownership: 0.196%View All Institutional Transactions APVO Stock - Frequently Asked Questions What is Aptevo Therapeutics' stock price forecast for 2023? 0 brokerages have issued 12 month price objectives for Aptevo Therapeutics' shares. Their APVO share price forecasts range from $13.00 to $13.00. On average, they predict the company's share price to reach $13.00 in the next year. This suggests a possible upside of 537.3% from the stock's current price. View analysts price targets for APVO or view top-rated stocks among Wall Street analysts. How have APVO shares performed in 2023? Aptevo Therapeutics' stock was trading at $2.32 on January 1st, 2023. Since then, APVO stock has decreased by 12.1% and is now trading at $2.04. View the best growth stocks for 2023 here. Are investors shorting Aptevo Therapeutics? Aptevo Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 105,200 shares, a decrease of 30.1% from the February 28th total of 150,400 shares. Based on an average daily volume of 91,100 shares, the short-interest ratio is presently 1.2 days. View Aptevo Therapeutics' Short Interest. When is Aptevo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our APVO earnings forecast. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) issued its quarterly earnings results on Thursday, March, 24th. The biotechnology company reported ($1.27) earnings per share for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO). What is Aptevo Therapeutics' stock symbol? Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO." Who are Aptevo Therapeutics' major shareholders? Aptevo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (0.25%), Morgan Stanley (0.22%), Bank of Montreal Can (0.20%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Aptevo Therapeutics? Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aptevo Therapeutics' stock price today? One share of APVO stock can currently be purchased for approximately $2.04. How much money does Aptevo Therapeutics make? Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $10.38 million and generates $12.29 million in revenue each year. How can I contact Aptevo Therapeutics? Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for the company is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503. This page (NASDAQ:APVO) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.